Biotech: Page 3
-
Regeneron commits $500M to new venture capital fund
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.
By Delilah Alvarado • April 15, 2024 -
Spencer Platt via Getty Images
Biotech IPOs bounced back in first quarter, but backlog remains
Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.
By Gwendolyn Wu • April 12, 2024 -
Explore the Trendline➔
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
TrendlineCOVID-19 vaccines
The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.
By BioPharma Dive staff -
luismmolina via Getty Images
Emerging biotechCentury buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
By Delilah Alvarado • April 11, 2024 -
PeopleImages via Getty Images
J&J, Rallybio partner on drug development for rare fetal condition
The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.
By Delilah Alvarado • April 10, 2024 -
whitehoune via Getty Images
Emerging biotechPureTech launches Seaport, hoping to create Karuna 2.0
The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.
By Jacob Bell • April 9, 2024 -
Adene Sanchez via Getty Images
Private biotech funding rises as venture firms deploy cash
Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Dive.
By Gwendolyn Wu • April 8, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 8, 2024 -
Michael M. Santiago via Getty Images
Emerging biotechContineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs
The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.
By Ben Fidler • April 4, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx to pull ALS drug from market in rare move
In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.
By Jacob Bell • April 4, 2024 -
JaysonPhotography via Getty Images
Paragon’s hub-and-spoke biotech model yields another reverse merger
Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.
By Jacob Bell • April 3, 2024 -
Kahan Shan via Getty Images
Diagonal starts up with $128M to make better ‘activator’ antibody drugs
The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.
By Gwendolyn Wu • April 3, 2024 -
Maximusnd via Getty Images
Roivant reveals positive immune drug data, share buyback plans
A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.
By Delilah Alvarado • April 2, 2024 -
Michael M. Santiago via Getty Images
Acorda files for bankruptcy, reveals asset sale plan
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
By Jacob Bell • April 2, 2024 -
Getty Images via Getty Images
A dementia-focused VC digs past amyloid for new kinds of brain drugs
The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.
By Michael Gibney • April 2, 2024 -
Meletios Verras via Getty Images
Ginkgo, in search of more cell therapy tools, buys another startup
A deal for Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.
By Gwendolyn Wu • April 2, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex moves kidney disease drug into late-stage testing
The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name.
By Delilah Alvarado • April 1, 2024 -
maciek905 via Getty Images
Boundless Bio breaks IPO lull with $100M fundraise
The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.
By Gwendolyn Wu • March 28, 2024 -
Permission granted by Gilead Sciences
Gilead bets on Xilio cancer drug as biotech restructures
Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.
By Ned Pagliarulo • March 28, 2024 -
Permission granted by Art Krieg
Emerging biotechBiotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.
By Ben Fidler • March 28, 2024 -
Maddie Meyer via Getty Images
Moderna gets Blackstone backing for flu vaccine R&D
An arm of the private equity firm pledged up to $750 million to support Moderna’s development of its mRNA technology for influenza shots.
By Delilah Alvarado • March 27, 2024 -
Michael M. Santiago via Getty Images
Obesity drugsViking stays in obesity drug race with early data for weight loss pill
The results are from a small Phase 1 study, but suggest Viking’s oral GLP-1 drug may not come with high rates of gastrointestinal side effects.
By Jonathan Gardner • March 26, 2024 -
Elizabeth Regan / Industry Dive
Stoke shares surge on updated results for Dravet drug
The biotech is trying to develop a Spinraza-like drug for the condition, a form of genetic epilepsy. Fresh data appear supportive of a high dose’s effectiveness.
By Ned Pagliarulo • March 26, 2024 -
Permission granted by Portal Bio
Q&ASQZ, Portal founder Armon Sharei on starting over in biotech
“I still care way too much about cell therapies,” said Sharei, weeks after his former startup, SQZ Biotechnologies, was liquidated.
By Gwendolyn Wu • March 26, 2024 -
Courtesy of AbbVie
AbbVie to buy immune drug developer Landos
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
By Delilah Alvarado • March 25, 2024 -
hapabapa via Getty Images
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024
Previous
